Filanesib TFA

• CAT Number: I014829
• CAS Number: 1781834-99-8
• Molecular Formula: C₂₂H₂₃F₅N₄O₄S
• Molecular Weight: 534.50
• Purity: ≥95%
• Target: Cytoskeleton
• IUPAC Name: (2S)-2-(3-aminopropyl)-5-(2,5-difluorophenyl)-N-methoxy-N-methyl-2-phenyl-1,3,4-thiadiazole-3-carboxamide;2,2,2-trifluoroacetic acid
• InChI: InChI=1S/C20H22F2N4O2S.C2HF3O2/c1-25(28-2)19(27)26-20(11-6-12-23,14-7-4-3-5-8-14)29-18(24-26)16-13-15(21)9-10-17(16)22;3-2(4,5)1(6)7/h3-5,7-10,13H,6,11-12,23H2,1-2H3;(H,6,7)/t20-;/m0./s1
• InChIKey: CIJUJPVFECBUKG-BDQAORGHSA-N
• SMILES: CN(C(=O)N1[C@](SC(=N1)C2=C(C=CC(=C2)F)F)(CCCN)C3=CC=CC=C3)OC.C(=O)(C(F)(F)F)O

Filanesib TFA (Cat No.:I014829) is a selective inhibitor of kinesin spindle protein (KSP), a motor protein crucial for cell division. By inhibiting KSP, Filanesib disrupts mitosis, leading to cell cycle arrest and ultimately cell death in rapidly dividing cancer cells. It has been investigated as a potential treatment for various cancers, including hematologic malignancies and solid tumors, due to its ability to target and inhibit cancer cell proliferation. Filanesib TFA has shown promising results in preclinical and early-phase clinical trials, though further research is required to evaluate its full therapeutic potential and safety.